Terumo Health Outcomes (THO) and Medis Medical Imaging have entered into a strategic partnership in the USA to drive utilisation of Terumo’s proprietary clinical decision support platform ePRISM and Medis’ quantitative flow ratio (QFR) technology.
The use of ePRISM and Medis QFR will be piloted at selected clinical sites, leveraging real-time data from electronic health records to provide prospective insights to help enhance patient care, the companies have said in a press release.
The press release adds that the partnership represents a significant step forward in enhancing clinical decision support capabilities, streamlining workflows and improving patient outcomes by providing interventional cardiologists with precise anatomical and physiological assessments of coronary artery disease (CAD).
QFR is an angiographic image-based approach that replacing the more invasive wire-based approach in assessing coronary physiology. It is also capable of evaluating multiple areas from the same images versus the wire-based approach which is vessel- and often lesion-specific.
The FAVOR trials, performed in the European Union (EU), have assessed the efficacy of the Medis QFR solution in practical use during and after an interventional procedure.
The FAVOR III China trial demonstrated a 34% reduction in major adverse cardiac events (MACE) in a one-year follow-up of patients treated with Medis QFR-guided versus standard angiography-guided procedures, and similar results were obtained after two years.
The FAVOR Trials, which used the first-generation QFR technology, demonstrated high accuracy compared to the pressure wire. This led to Medis QFR being approved and reimbursed in Japan, and included in the 2024 European Society of Cardiology (ESC) guidelines for chronic coronary syndromes with a class I recommendation.
The PIONEER IV trial, a 2,540-patient study, aims to evaluate the superiority of the next-generation QFR technology—for both pre- and post-procedure stenting recommendations—which will be integrated with THO’s ePRISM platform.
“This collaboration underscores Terumo’s commitment to building an innovative care operating system that not only improves clinical outcomes but also streamlines the entire care pathway,” said Ryan Graver, senior divisional vice president, THO. “By utilising our ePRISM platform alongside Medis’ QFR technology and TIS’ devices, we are equipping clinicians with a comprehensive suite that enhances procedural efficiency and patient outcomes. Together, we are redefining what’s possible in cardiovascular care.”
“At Medis Medical Imaging, we are thrilled to partner with Terumo Health Outcomes to push the boundaries of cardiovascular imaging and decision support,” said Maya Barley, CEO of Medis Medical Imaging. “This collaboration provides a comprehensive solution that enhances diagnostic accuracy and treatment planning. It highlights our dedication to improving patient care through innovation, working together with our worldwide network of partners.”
THO is a division of Terumo Interventional Systems.
